There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mesoblast Ltd (NASDAQ: MESO) and Aduro BioTech (NASDAQ: ADRO) with bullish sentiments.
Mesoblast Ltd (NASDAQ: MESO)
In a report released today, Jason Kolbert from H.C. Wainwright maintained a Buy rating on Mesoblast Ltd (NASDAQ: MESO), with a price target of $17. The company’s shares closed yesterday at $5.54.
Kolbert observed:
“Our therapeutic models are patient-based and reflect our assumptions for the product launch dates, product attributes, and pricing, to determine the future revenue streams. We apply a probability of success in these models.”
According to TipRanks.com, Kolbert is ranked 0 out of 5 stars with an average return of -2.3% and a 38.3% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Anavex Life Sciences, Can-Fite BioPharma, and Cytori Therap.
Currently, the analyst consensus on Mesoblast Ltd is Strong Buy and the average price target is $15.20, representing a 174.4% upside.
In a report issued on June 7, Maxim Group also maintained a Buy rating on the stock with a $14 price target.
See today’s analyst top recommended stocks >>
Aduro BioTech (NASDAQ: ADRO)
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Aduro BioTech (NASDAQ: ADRO) today and set a price target of $9.50. The company’s shares closed yesterday at $8.
Pantginis observed:
“Valuation and risks to price target achievement. We maintain our Buy rating, and a $9.50 price target. This valuation reflects the revaluation of the company following the discontinuation of CRS-207 (lead value driver in 2017). Our target is based on our clinical net present value (NPV) model, which derives value from across Aduro’s assets but primarily for ADU-S100. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile.”
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -9.0% and a 36.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Aduro BioTech has an analyst consensus of Moderate Buy, with a price target consensus of $11.25.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
